Mutant huntingtin fragment selectively suppresses Brn-2 POU domain transcription factor to mediate hypothalamic cell dysfunction

Human Molecular Genetics

Volumn 19, Issue 11, 2010, Pages 2099-2112

  Yamanaka, Tomoyuki ^a,b   Tosaki, Asako ^a   Miyazaki, Haruko ^a   Kurosawa, Masaru ^a   Furukawa, Yoshiaki ^a,b   Yamada, Mizuki ^a   Nukina, Nobuyuki ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^b RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HUNTINGTIN; MESSENGER RNA; MUTANT PROTEIN; NEUROPEPTIDE; PROTEIN BRN 2; TRANSCRIPTION FACTOR POU; UNCLASSIFIED DRUG; HOMEODOMAIN PROTEIN; HUNTINGTON PROTEIN, MOUSE; NERVE PROTEIN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR BRN-2;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DNA BINDING; HUNTINGTON CHOREA; HYPOTHALAMUS; MALE; MOUSE; NERVE CELL DIFFERENTIATION; NEUROPATHOLOGY; NEUROSECRETORY CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ANIMAL; CYTOLOGY; FLUORESCENCE MICROSCOPY; GEL MOBILITY SHIFT ASSAY; GENETICS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METABOLISM; MUTATION; NERVE CELL; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

MUS;

ANIMALS; DNA; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HOMEODOMAIN PROTEINS; HUNTINGTON DISEASE; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MICE; MICROSCOPY, FLUORESCENCE; MUTATION; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; POU DOMAIN FACTORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77953499072     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq087     Document Type: Article

References (52)

1. Walker, F.O. (2007) Huntington's disease. Lancet, 369, 218-228.
2. Landles, C. and Bates, G.P. (2004) Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep., 5, 958-963.
3. Bauer, P.O. and Nukina, N. (2009) The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J. Neurochem., 110, 1737-1765.
4. Luthi-Carter, R., Hanson, S.A., Strand, A.D., Bergstrom, D.A., Chun, W., Peters, N.L., Woods, A.M., Chan, E.Y., Kooperberg, C., Krainc, D. et al. (2002) Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet., 11, 1911-1926. Human Molecular Genetics, 2010, Vol. 19, No. 11 2111
5. Chan, E.Y., Luthi-Carter, R., Strand, A., Solano, S.M., Hanson, S.A., DeJohn, M.M., Kooperberg, C., Chase, K.O., DiFiglia, M., Young, A.B. et al. (2002) Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Hum. Mol. Genet., 11, 1939-1951.
6. Kotliarova, S., Jana, N.R., Sakamoto, N., Kurosawa, M., Miyazaki, H., Nekooki, M., Doi, H., Machida, Y., Wong, H.K., Suzuki, T. et al. (2005) Decreased expression of hypothalamic neuropeptides in Huntington disease transgenic mice with expanded polyglutamine-EGFP fluorescent aggregates. J. Neurochem., 93, 641-653.
7. Kuhn, A., Goldstein, D.R., Hodges, A., Strand, A.D., Sengstag, T., Kooperberg, C., Becanovic, K., Pouladi, M.A., Sathasivam, K., Cha, J.H. et al. (2007) Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet., 16, 1845-1861.
8. Nucifora, F.C. Jr, Sasaki, M., Peters, M.F., Huang, H., Cooper, J.K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V.L. et al. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science, 291, 2423-2428.
9. Steffan, J.S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.Z., Gohler, H., Wanker, E.E., Bates, G.P., Housman, D.E. and Thompson, L.M. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA, 97, 6763-6768.
10. Suhr, S.T., Senut, M.C., Whitelegge, J.P., Faull, K.F., Cuizon, D.B. and Gage, F.H. (2001) Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. J. Cell. Biol., 153, 283-294.
11. van Roon-Mom, W.M., Reid, S.J., Jones, A.L., MacDonald, M.E., Faull, R.L. and Snell, R.G. (2002) Insoluble TATA-binding protein accumulation in Huntington's disease cortex. Brain. Res. Mol. Brain. Res., 109, 1-10.
12. Schaffar, G., Breuer, P., Boteva, R., Behrends, C., Tzvetkov, N., Strippel, N., Sakahira, H., Siegers, K., Hayer-Hartl, M. and Hartl, F.U. (2004) Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol. Cell., 15, 95-105.
13. Dunah, A.W., Jeong, H., Griffin, A., Kim, Y.M., Standaert, D.G., Hersch, S.M., Mouradian, M.M., Young, A.B., Tanese, N. and Krainc, D. (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science, 296, 2238-2243.
14. Li, S.H., Cheng, A.L., Zhou, H., Lam, S., Rao, M., Li, H. and Li, X.J. (2002) Interaction of Huntington disease protein with transcriptional activator Sp1. Mol. Cell. Biol., 22, 1277-1287.
15. Yamanaka, T., Miyazaki, H., Oyama, F., Kurosawa, M., Washizu, C., Doi, H. and Nukina, N. (2008) Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor. EMBO J., 27, 827-839.
16. Cha, J.H. (2000) Transcriptional dysregulation in Huntington's disease. Trends Neurosci., 23, 387-392.
17. Sugars, K.L. and Rubinsztein, D.C. (2003) Transcriptional abnormalities in Huntington disease. Trends. Genet., 19, 233-238.
18. Andersen, B. and Rosenfeld, M.G. (2001) POU domain factors in the neuroendocrine system: lessons from developmental biology provide insights into human disease. Endocr. Rev., 22, 2-35.
19. Nakai, S., Kawano, H., Yudate, T., Nishi, M., Kuno, J., Nagata, A., Jishage, K., Hamada, H., Fujii, H., Kawamura, K. et al. (1995) The POU domain transcription factor Brn-2 is required for the determination of specific neuronal lineages in the hypothalamus of the mouse. Genes. Dev., 9, 3109-3121.
20. Furukawa, Y., Kaneko, K., Matsumoto, G., Kurosawa, M. and Nukina, N. (2009) Cross-seeding fibrillation of Q/N-rich proteins offers new pathomechanism of polyglutamine diseases. J. Neurosci., 29, 5153-5162.
21. Busch, A., Engemann, S., Lurz, R., Okazawa, H., Lehrach, H. and Wanker, E.E. (2003) Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington's disease. J. Biol. Chem., 278, 41452-41461.
22. Okazawa, H., Rich, T., Chang, A., Lin, X., Waragai, M., Kajikawa, M., Enokido, Y., Komuro, A., Kato, S., Shibata, M. et al. (2002) Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death. Neuron, 34, 701-713.
23. Waragai, M., Lammers, C.H., Takeuchi, S., Imafuku, I., Udagawa, Y., Kanazawa, I., Kawabata, M., Mouradian, M.M. and Okazawa, H. (1999) PQBP-1, a novel polyglutamine tract-binding protein, inhibits transcription activation by Brn-2 and affects cell survival. Hum. Mol. Genet., 8, 977-987.
24. Zhai, W., Jeong, H., Cui, L., Krainc, D. and Tjian, R. (2005) In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell, 123, 1241-1253.
25. Schonemann, M.D., Ryan, A.K., McEvilly, R.J., O'Connell, S.M., Arias, C.A., Kalla, K.A., Li, P., Sawchenko, P.E. and Rosenfeld, M.G. (1995) Development and survival of the endocrine hypothalamus and posterior pituitary gland requires the neuronal POU domain factor Brn-2. Genes Dev., 9, 3122-3135.
26. Wood, N.I., Goodman, A.O., van der Burg, J.M., Gazeau, V., Brundin, P., Bjorkqvist, M., Petersen, A., Tabrizi, S.J., Barker, R.A. and Morton, A.J. (2008) Increased thirst and drinking in Huntington's disease and the R6/2 mouse. Brain Res. Bull., 76, 70-79.
27. van der Burg, J.M., Bacos, K., Wood, N.I., Lindqvist, A., Wierup, N., Woodman, B., Wamsteeker, J.I., Smith, R., Deierborg, T., Kuhar, M.J. et al. (2008) Increased metabolism in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis., 29, 41-51.
28. Keith, B., Adelman, D.M. and Simon, M.C. (2001) Targeted mutation of the murine arylhydrocarbon receptor nuclear translocator 2 (Arnt2) gene reveals partial redundancy with Arnt. Proc. Natl Acad. Sci. USA, 98, 6692-6697.
29. Hosoya, T., Oda, Y., Takahashi, S., Morita, M., Kawauchi, S., Ema, M., Yamamoto, M. and Fujii-Kuriyama, Y. (2001) Defective development of secretory neurones in the hypothalamus of Arnt2-knockout mice. Genes Cells, 6, 361-374.
30. Michaud, J.L., DeRossi, C., May, N.R., Holdener, B.C. and Fan, C.M. (2000) ARNT2 acts as the dimerization partner of SIM1 for the development of the hypothalamus. Mech. Dev., 90, 253-261.
31. Michaud, J.L., Rosenquist, T., May, N.R. and Fan, C.M. (1998) Development of neuroendocrine lineages requires the bHLH-PAS transcription factor SIM1. Genes. Dev., 12, 3264-3275.
32. Li, S.H. and Li, X.J. (2004) Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet., 20, 146-154.
33. Harjes, P. and Wanker, E.E. (2003) The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem. Sci., 28, 425-433.
34. Yu, Z.X., Li, S.H., Nguyen, H.P. and Li, X.J. (2002) Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Hum. Mol. Genet., 11, 905-914.
35. Obrietan, K. and Hoyt, K.R. (2004) CRE-mediated transcription is increased in Huntington's disease transgenic mice. J. Neurosci., 24, 791-796.
36. Qiu, Z., Norflus, F., Singh, B., Swindell, M.K., Buzescu, R., Bejarano, M., Chopra, R., Zucker, B., Benn, C.L., DiRocco, D.P. et al. (2006) Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. J. Biol. Chem., 281, 16672-16680.
37. Bae, B.I., Xu, H., Igarashi, S., Fujimuro, M., Agrawal, N., Taya, Y., Hayward, S.D., Moran, T.H., Montell, C., Ross, C.A. et al. (2005) p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron, 47, 29-41.
38. Holbert, S., Denghien, I., Kiechle, T., Rosenblatt, A., Wellington, C., Hayden, M.R., Margolis, R.L., Ross, C.A., Dausset, J., Ferrante, R.J. et al. (2001) The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proc. Natl Acad. Sci. USA, 98, 1811-1816.
39. Sugitani, Y., Nakai, S., Minowa, O., Nishi, M., Jishage, K., Kawano, H., Mori, K., Ogawa, M. and Noda, T. (2002) Brn-1 and Brn-2 share crucial roles in the production and positioning of mouse neocortical neurons. Genes Dev., 16, 1760-1765.
40. McEvilly, R.J., de Diaz, M.O., Schonemann, M.D., Hooshmand, F. and Rosenfeld, M.G. (2002) Transcriptional regulation of cortical neuron migration by POU domain factors. Science, 295, 1528-1532.
41. Tagawa, K., Marubuchi, S., Qi, M.L., Enokido, Y., Tamura, T., Inagaki, R., Murata, M., Kanazawa, I., Wanker, E.E. and Okazawa, H. (2007) The induction levels of heat shock protein 70 differentiate the vulnerabilities to mutant huntingtin among neuronal subtypes. J. Neurosci., 27, 868-880.
42. Bjorkqvist, M., Petersen, A., Bacos, K., Isaacs, J., Norlen, P., Gil, J., Popovic, N., Sundler, F., Bates, G.P., Tabrizi, S.J. et al. (2006) Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum. Mol. Genet., 15, 1713-1721.
43. Saleh, N., Moutereau, S., Durr, A., Krystkowiak, P., Azulay, J.P., Tranchant, C., Broussolle, E., Morin, F., Bachoud-Levi, A.C. and Maison, P. (2009) Neuroendocrine disturbances in Huntington's disease. PLoS One, 4, e4962.
44. Petersen, A. and Bjorkqvist, M. (2006) Hypothalamic-endocrine aspects in Huntington's disease. Eur. J. Neurosci., 24, 961-967.
45. Donaldson, Z.R. and Young, L.J. (2008) Oxytocin, vasopressin, and the neurogenetics of sociality. Science, 322, 900-904.
46. Timmers, H.J., Swaab, D.F., van de Nes, J.A. and Kremer, H.P. (1996) Somatostatin 1-12 immunoreactivity is decreased in the hypothalamic lateral tuberal nucleus of Huntington's disease patients. Brain Res., 728, 141-148.
47. Petersen, A., Gil, J., Maat-Schieman, M.L., Bjorkqvist, M., Tanila, H., Araujo, I.M., Smith, R., Popovic, N., Wierup, N., Norlen, P. et al. (2005) Orexin loss in Huntington's disease. Hum. Mol. Genet., 14, 39-47.
48. Sato, T., Miura, M., Yamada, M., Yoshida, T., Wood, J.D., Yazawa, I., Masuda, M., Suzuki, T., Shin, R.M., Yau, H.J. et al. (2009) Severe neurological phenotypes of Q129 DRPLA transgenic mice serendipitously created by en masse expansion of CAG repeats in Q76 DRPLA mice. Hum. Mol. Genet., 18, 723-736.
49. The FANTOM Consortium, Carninci, P., Kasukawa, T., Katayama, S., Gough, J., Frith, M.C., Maeda, N., Oyama, R. et al. (2005) The transcriptional landscape of the mammalian genome. Science, 309, 1559-1563.
50. Doi, H., Mitsui, K., Kurosawa, M., Machida, Y., Kuroiwa, Y. and Nukina, N. (2004) Identification of ubiquitin-interacting proteins in purified polyglutamine aggregates. FEBS Lett., 571, 171-176.
51. Yamanaka, T., Horikoshi, Y., Izumi, N., Suzuki, A., Mizuno, K. and Ohno, S. (2006) Lgl mediates apical domain disassembly by suppressing the PAR-3-aPKC-PAR-6 complex to orient apical membrane polarity. J. Cell. Sci., 119, 2107-2118.
52. Oyama, F., Miyazaki, H., Sakamoto, N., Becquet, C., Machida, Y., Kaneko, K., Uchikawa, C., Suzuki, T., Kurosawa, M., Ikeda, T. et al. (2006) Sodium channel beta4 subunit: down-regulation and possible involvement in neuritic degeneration in Huntington's disease transgenic mice. J. Neurochem., 98, 518-529.